

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10700143
	Filing Date		2003-11-03
	First Named Inventor	Robert M. Lorence	
	Art Unit	1648	
	Examiner Name	N. Kinsey White	
	Attorney Docket Number	18029	

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²ⁱ	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10700143
Filing Date	2003-11-03
First Named Inventor	Robert M. Lorence
Art Unit	1648
Examiner Name	N. Kinsey White
Attorney Docket Number	18029

1	Freeman, et al., "Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme", Molecular Therapy, Vol. 13, No. 1, January 2006, pages 221-228.	<input type="checkbox"/>
2	Newcastle Disease Virus, (PDQ®), General Information, National Cancer Institute, Last Modified December 4, 2007, pages 1-6, http://www.cancer.gov/cancertopics/pdq/cam/NDV/HealthProfessional/page3	<input type="checkbox"/>
3	Office Action dated June 29, 2007 for US Patent Application No. 10/518,732, pages 1-13.	<input type="checkbox"/>
4	Omar, et al., "An Overview on the Development of Newcastle Disease Virus as an Anti-Cancer Therapy", Malaysian Journal of Medical Sciences, Vol. 10, No. 1, January 2003, pages 4-12.	<input type="checkbox"/>
5	Schirmacher, et al., "Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus", Gene Therapy, Vol. 6, 1999, pages 63-73.	<input type="checkbox"/>
6	Schirmacher, et al., "Antitumor effects of Newcastle Disease Virus in vivo: Local versus systemic effects", International Journal of Oncology, Vol. 18, 2001, pages 945-952.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.